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Thank you for your interest in our case report.1 We did state that the cause of death 
was idiopathic pulmonary fibrosis (IPF) due to typical clinical and radiological 
findings. We agree that there appears to be some overlap in pathogenetic 
This is the peer reviewed version of the following article: Affleck, A., et al. "Comment on 'Fatal, 
incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate 
for psoriasis'", Clinical and Experimental Dermatology (2019), which has been published in final 
form at https://doi.org/10.1111/ced.13993. This article may be used for non-commercial purposes 
in accordance with Wiley Terms and Conditions for Self-Archiving.
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mechanisms between psoriasis and IPF e.g. raised IL-17; indeed, the possibility of a 
restrictive form of psoriatic lung disease has been raised although it appears to be 
rare. Significantly, both cutaneous psoriasis and pulmonary changes can improve 
with anti-interleukin (IL) 12/IL-23 or IL-17 antibodies.2 A recent study reported that 
patients with psoriasis may be at increased risk of developing interstitial lung disease 
(most commonly IPF) independent of previous or concomitant exposure to 
immunosuppressants.3  We agree that theoretically, low blood folate levels could be 
a risk for developing pneumonitis or potentially a chronic interstitial pneumonia 
exacerbated by methotrexate. However, as is standard clinical practice, our patient 
had folic acid 5mg daily throughout his methotrexate therapy and given the elapsed 
time on therapy he did not have a pneumonitis. We do not believe that there is 
sufficient evidence to suggest higher daily doses of folic acid for patients having 
methotrexate for psoriasis. Methotrexate-induced pneumonitis appears to be 
idiosyncratic and so preventative measures are not likely to be helpful for the vast 
majority of patients. The remote possibility of an interstitial lung disease (ILD) 
associated with psoriasis does not justify routine radiological screening and 
biomarkers, although desirable, e.g. serum KL-6, are not reliable or validated for use 
in clinical practice. We do advocate the general measure of cessation of cigarette 
smoking in all patients with psoriasis whether or not they are on systemic therapy as 
this may reduce the chance of developing an ILD such as IPF or separately COPD 
(another recently proposed extracutaneous manifestation of psoriasis). Further 
research may help clarify this important and complex topic; we wonder whether the 
BADBIR large prospective database could shed light on the incidence of ILD in 
patients with moderate to severe psoriasis?  
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